Project Grant R43CA314462
Award Date 9/1/26
Completion Date 5/31/27
Dollars Obligated $400K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
College Station, TX, USA
Similar Awards
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $918,976 in funding to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to characterize plant-based phenolic alkanones as next-generation sun protectants for skin cancer prevention. The award period runs from July 15, 2024 to July 14, 2027. The funding supports research activities to develop and evaluate novel, plant-derived compounds as...
- The federal Project Grant award of $1,187,274.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant is supporting research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to characterize plant-based phenolic alkanones as next-generation sun protectants for skin cancer prevention. The research project aims to develop novel, plant-derived compounds that can serve as...
- The National Cancer Institute awarded the University of Pittsburgh $673,522 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to support comprehensive biochemical and structural analysis of nucleotide excision repair (NER), the primary human pathway for removing DNA lesions caused by solar UV irradiation and environmental toxins. The recipient will characterize the dynamic progression of NER from damage recognition and verification through dual incision, using...
- The National Cancer Institute awarded the University of Arizona $399,712 on May 19, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct exploratory research investigating the occurrence and role of endogenous chloramine derivatives in skin inflammation and photocarcinogenesis. The project focuses on a novel chlorination product, chloro-cis-urocanic acid (CL-CIS-UCA), formed upon co-exposure of human skin to solar ultraviolet radiation and environmental...
- The National Cancer Institute, within the Department of Health and Human Services, awarded The University of Texas MD Anderson Cancer Center $704,028 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial comparing topical fluorouracil (5-FU) with a combination therapy of fluorouracil and calcipotriene (COMBOTX) for treating actinic keratoses, digitally-enabled through artificial intelligence-supported image analysis. The...
- The National Cancer Institute awarded the University of Texas at Arlington $565,569 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 1, 2026, for the design and synthesis of light-responsive osmium compounds to enable optical image-guided surgery and phototherapy in cancer treatment. The project will develop osmium compounds that luminesce at near-infrared wavelengths where tissue is most transparent, with the compounds engineered to be nontoxic to healthy tissue...
- The National Cancer Institute awarded Daybreak Pharmaceuticals Inc. $303,345 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a first-in-class synthetic RNA-based therapy targeting the mutagenic translesion synthesis pathway to enhance chemotherapy efficacy in non-small cell lung cancer. The project delivers proof-of-concept evaluation of translesion synthesis inhibition using a nucleic acid construct encoding a dominant-negative REV1 C-terminal...
- The National Science Foundation (NSF) awarded a $1,000,000 Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Soliome Inc., a small business located in San Francisco, CA. The grant supports the development of biocompatible and biodegradable ultraviolet (UV) filters for use in skincare, cosmetics, and sunscreen products. The project aims to create novel, safe UV materials as an alternative to current petroleum-based photo-protectants that can...
- The National Cancer Institute awarded Tiburon Bio Inc. $305,488 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a sustained-release multidomain peptide hydrogel formulation combining an iNOS inhibitor (L-NIL) and a STING-agonist (CDN) for use with immune checkpoint inhibitor monoclonal antibodies in neoadjuvant immunotherapy for resectable oral cancers. The work aims to enhance immune priming to control residual disease following tumor resection and...
- The National Cancer Institute awarded the University of Miami $522,368 on August 11, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate how RNA polymerase II bypasses transcription-blocking lesions caused by ultraviolet radiation and the role of transcription-coupled nucleotide excision repair (TC-NER) in this process. The research aims to understand how the acetyltransferase P300 regulates RNA polymerase II stalling at UV-induced DNA lesions, how its...